Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cooper

Showing results (181-190 of 319) with videos related to

Pageof 32
Sort By:
Human Vaccines & Immunotherapeutics|August 8, 2018
Safety, tolerability, and immunogenicity of a novel 4-antigen <i>Staphylococcus aureus</i> vaccine (SA4Ag) in healthy Japanese adultsMegumi Inoue, Takuma Yonemura, James Baber, et al.
Cellular Immunology|June 10, 2006
Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junctionDavid Cooper, Joseph C Mester, Min Guo, et al.
Journal of Virology|December 8, 2006
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocationsDavid K Clarke, Farooq Nasar, Margaret Lee, et al.
The British Journal of Ophthalmology|February 18, 2018
Clear lens extraction for the management of primary angle closure glaucoma: surgical technique and refractive outcomes in the EAGLE cohortAlexander C Day, David Cooper, Jennifer Burr, et al.
Antiviral Therapy|May 4, 2005
Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patientsMark Boyd, Piroon Mootsikapun, David Burger, et al.
Vaccine|February 2, 2017
SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodiesElizabeth Begier, David Joshua Seiden, Michael Patton, et al.
Vaccine|April 15, 2024
Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 studyJeffrey Baker, Negar Aliabadi, Iona Munjal, et al.
The British Journal of Ophthalmology|April 7, 2022
Predictors of long-term intraocular pressure control after lens extraction in primary angle closure glaucoma: results from the EAGLE trialWilliam G Mitchell, Augusto Azuara-Blanco, Paul J Foster, et al.
Nature Communications|June 23, 2022
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccineChaitanya Kurhade, Jing Zou, Hongjie Xia, et al.
AIDS Research and Human Retroviruses|February 1, 2007
Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patientsJoseph C Gathe, Gerald Pierone, Peter Piliero, et al.
Pageof 32

Showing results (181-190 of 319) with videos related to

Sort By:
Pageof 32
Human Vaccines & Immunotherapeutics|August 8, 2018
Safety, tolerability, and immunogenicity of a novel 4-antigen <i>Staphylococcus aureus</i> vaccine (SA4Ag) in healthy Japanese adultsMegumi Inoue, Takuma Yonemura, James Baber, et al.
Cellular Immunology|June 10, 2006
Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junctionDavid Cooper, Joseph C Mester, Min Guo, et al.
Journal of Virology|December 8, 2006
Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocationsDavid K Clarke, Farooq Nasar, Margaret Lee, et al.
The British Journal of Ophthalmology|February 18, 2018
Clear lens extraction for the management of primary angle closure glaucoma: surgical technique and refractive outcomes in the EAGLE cohortAlexander C Day, David Cooper, Jennifer Burr, et al.
Antiviral Therapy|May 4, 2005
Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patientsMark Boyd, Piroon Mootsikapun, David Burger, et al.
Vaccine|February 2, 2017
SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodiesElizabeth Begier, David Joshua Seiden, Michael Patton, et al.
Vaccine|April 15, 2024
Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 studyJeffrey Baker, Negar Aliabadi, Iona Munjal, et al.
The British Journal of Ophthalmology|April 7, 2022
Predictors of long-term intraocular pressure control after lens extraction in primary angle closure glaucoma: results from the EAGLE trialWilliam G Mitchell, Augusto Azuara-Blanco, Paul J Foster, et al.
Nature Communications|June 23, 2022
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccineChaitanya Kurhade, Jing Zou, Hongjie Xia, et al.
AIDS Research and Human Retroviruses|February 1, 2007
Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patientsJoseph C Gathe, Gerald Pierone, Peter Piliero, et al.
Pageof 32